Moderna, Inc. (MRNA) — SEC Filings

Latest SEC filings for Moderna, Inc. (MRNA), explained in plain English.

Sentiment Overview: 1 bullish, 2 bearish, 25 neutral, 1 mixed

Recent Filings (29)

• Moderna Enters Material Definitive Agreement — 8-K · 2025-11-24T00:00:00.000Z [neutral] Risk: medium
  On November 19, 2025, Moderna, Inc. entered into a material definitive agreement, creating a direct financial obligation. The filing details this agreement and
• 8-K Filing — 8-K · 2025-11-20T00:00:00.000Z [neutral]
• 8-K Filing — 8-K · 2025-11-13T00:00:00.000Z [neutral]
• Moderna's Q3 Loss Widens Amidst Revenue Dip, R&D Spend Cuts — 10-Q · 2025-11-06T00:00:00.000Z [bearish] Risk: high
  Moderna, Inc. (MRNA) reported a significant net loss of $200 million for the three months ended September 30, 2025, a substantial decline from a net income of $
• Moderna Files Proxy Materials — DEFA14A · 2025-10-20T00:00:00.000Z [neutral] Risk: low
  Moderna, Inc. filed a Definitive Additional Materials proxy statement on October 20, 2025. This filing relates to the company's proxy materials, which are typic
• Moderna Seeks Shareholder Nod for Underwater Option Exchange — DEF 14A · 2025-10-15T00:00:00.000Z [mixed] Risk: medium
  Moderna, Inc. (MRNA) is proposing a one-time stock option exchange program for its non-Executive Committee employees to address significantly 'underwater' stock
• Moderna's Sales Plummet 62% Amid Post-Pandemic Vaccine Shift — 10-Q · 2025-08-01T00:00:00.000Z [bearish] Risk: high
  Moderna, Inc. reported product sales of $1.1 billion for the three months ended June 30, 2025, a significant decrease from $2.9 billion in the same period of 20
• Moderna Inc. Files 8-K on Shareholder Votes — 8-K · 2025-05-05T00:00:00.000Z [neutral] Risk: low
  Moderna, Inc. filed an 8-K on May 5, 2025, reporting on matters submitted to a vote of security holders as of April 30, 2025. The filing details the company's p
• Moderna Files Q1 2025 10-Q — 10-Q · 2025-05-01T00:00:00.000Z [neutral] Risk: medium
  Moderna, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and business operations for the first quarter of 202
• Moderna Files 2025 Proxy Statement: Executive Compensation Details — DEF 14A · 2025-03-11T00:00:00.000Z [neutral] Risk: medium
  Moderna, Inc. filed its Definitive Proxy Statement (DEF 14A) on March 11, 2025, for the fiscal year ending December 31, 2024. The filing details executive compe
• Moderna Files 2024 10-K — 10-K · 2025-02-21T00:00:00.000Z [neutral] Risk: medium
  Moderna, Inc. filed its 10-K for the fiscal year ending December 31, 2024, on February 21, 2025. The company, headquartered at 325 Binney Street, Cambridge, MA,
• Moderna Files 8-K on Financials — 8-K · 2025-02-14T00:00:00.000Z [neutral] Risk: low
  Moderna, Inc. filed an 8-K on February 14, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and ex
• Moderna, Inc. Files 8-K on Financials — 8-K · 2025-01-13T00:00:00.000Z [neutral] Risk: low
  On January 13, 2025, Moderna, Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes financial statements and
• Moderna Files Q3 2024 10-Q with Financial Updates — 10-Q · 2024-11-07T00:00:00.000Z [neutral] Risk: medium
  Moderna, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its development progra
• Moderna 8-K: Executive Changes & Financials — 8-K · 2024-10-02T00:00:00.000Z [neutral] Risk: medium
  Moderna, Inc. filed an 8-K on October 2, 2024, reporting on events as of September 28, 2024. The filing primarily concerns the departure of certain officers, th
• Moderna Files 8-K: Financials & Reg FD Update — 8-K · 2024-09-12T00:00:00.000Z [neutral] Risk: low
  On September 12, 2024, Moderna, Inc. filed an 8-K report to disclose information regarding financial statements and exhibits, as well as a Regulation FD disclos
• Moderna Files Q2 2024 10-Q — 10-Q · 2024-08-01T00:00:00.000Z [neutral] Risk: medium
  Moderna, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and business operations for the second quarter of 202
• Moderna 8-K: Board Changes and Executive Compensation — 8-K · 2024-07-23T00:00:00.000Z [neutral] Risk: medium
  On July 19, 2024, Moderna, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the departure of
• Moderna Files 8-K: Shareholder Vote & Financials — 8-K · 2024-05-09T00:00:00.000Z [neutral] Risk: low
  Moderna, Inc. filed an 8-K on May 9, 2024, reporting on events that occurred on May 6, 2024. The filing indicates that the company submitted matters to a vote o
• Moderna Q1 2024: Sales Dip Slightly to $1.1B — 10-Q · 2024-05-02T00:00:00.000Z [neutral] Risk: medium
  Moderna, Inc. filed its 10-Q for the period ending March 31, 2024. The company reported product sales of $1.1 billion for the first quarter of 2024, a decrease
• SC 13G/A Filing — SC 13G/A · 2024-04-10T00:00:00.000Z [neutral]
• Moderna, Inc. DEF 14A Filing — DEF 14A · 2024-03-21T00:00:00.000Z [neutral] Risk:
  Moderna, Inc. (MRNA) filed a Proxy Statement (DEF 14A) with the SEC on March 21, 2024. Moderna, Inc. filed a DEF 14A with the SEC on March 21, 2024. The filing
• Moderna, Inc. Files 2023 Annual Report on Form 10-K — 10-K · 2024-02-23T00:00:00.000Z [neutral] Risk: medium
  Moderna, Inc. (MRNA) filed a Annual Report (10-K) with the SEC on February 23, 2024. Moderna, Inc. reported its 2023 fiscal year results on February 23, 2024. T
• Moderna Files 8-K on Financial Condition and Operations — 8-K · 2024-02-22T00:00:00.000Z [neutral] Risk: low
  Moderna, Inc. filed an 8-K on February 22, 2024, reporting on its results of operations and financial condition. The filing indicates that the company, based in
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• Moderna CEO Bancel Holds 30.38M Shares, Signals Confidence — SC 13G/A · 2024-02-07T00:00:00.000Z [bullish]
  Stéphane Bancel, CEO of Moderna, Inc., filed an amended SC 13G/A on February 7, 2024, disclosing his beneficial ownership of 30,384,866 shares of Moderna's comm
• Baillie Gifford Amends Moderna Stake, Signals Ownership Change — SC 13G/A · 2024-01-29T00:00:00.000Z [neutral]
  Baillie Gifford & Co, a prominent investment management firm, filed an amended SC 13G/A on January 29, 2024, indicating a change in their beneficial ownership o
• BlackRock Updates Passive Stake in Moderna (MRNA) via SC 13G/A — SC 13G/A · 2024-01-29T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended SC 13G/A on January 29, 2024, indicating its ownership of Moderna, Inc. common stock as of December 31, 2023. This filing, an am
• Moderna 8-K Signals Upcoming Financial Disclosure — 8-K · 2024-01-08T00:00:00.000Z [neutral]
  Moderna, Inc. filed an 8-K on January 8, 2024, to report an event related to its 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure'.